Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 16 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Novel regimen appears to be safe and effective in treating esophageal cancer

Oxaliplatin, administered with protracted-infusion fluorouracil and radiation, is safe, tolerable, and seems effective against primary esophageal carcinoma, claims a team from Buffalo, New York, USA.

News image

fiogf49gjkf04

The researchers investigated the use of oxaliplatin (OXP) in combination with protracted-infusion (PI) fluorouracil (5-FU) and radiation in patients with esophageal cancer.

The findings of the trial were reported in the latest issue of the Journal of Clinical Oncology.

A total of 38 therapeutically naïve esophageal carcinoma patients were included in the study. Of these, 22 were noninvasively staged as IV and 16 were noninvasively staged as II and III.

Initial doses and schedules for cycle 1 consisted of OXP 85 mg/m2 on days 1, 15, and 29, and PI 5-FU 180 mg/m2 for 24 hours for 35 days. This was in addition to external-beam radiation therapy (XRT), 1.8 Gy in 28 fractions, starting on day 8.

Some 36 patients completed cycle 1.

Eligible patients could undergo an operation or begin cycle 2 without XRT.

Postoperative patients were eligible for cycle 2.

It was found that 29 patients started cycle 2, and 24 patients completed cycle 2.

81% of patients no longer had esophageal cancer after cycle 1.
Journal of Clinical Oncology
Stage IV patients were allowed 3 cycles in the absence of disease progression.

OXP and 5-FU increases were based on dose-limiting toxicity encountered in cohorts of 3 consecutive patients.

The team found that combined-modality therapy was well tolerated, but dose-limiting toxicity prevented OXP and 5-FU escalation.

No grade 4 hematologic toxicity was noted.

A total of eleven grade 3 and two grade 4 clinical toxicities were noted in 8 patients.

After cycle 1, 81% of patients had no cancer in the esophageal mucosa.

Some 13 patients underwent an operation with intent to resect the esophagus. Of these, 38% of the patients exhibited pathologic complete responses.

Dr Nikhil I. Khushalani, of the Roswell Park Cancer Institute, Buffalo, said on behalf of fellow authors, "OXP 85 mg/m2 on days 1, 15, and 29, administered with PI 5-FU and XRT is safe, tolerable, and seems effective against primary esophageal carcinoma."

"The role of OXP in multimodality regimens against esophageal carcinoma deserves further evaluation," it was concluded.

J Clin Oncol 2002; 20(12): 2844-50
19 June 2002

Go to top of page Email this page Email this page to a colleague

 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 16 January 2018 
Bundle of care in GI cancer surgery
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 15 January 2018 
Risks of death after liver transplants for liver cancer
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Colonoscopy after colorectal cancer resection
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
PPI and Alzheimer's disease
 21 December 2017 
Health management for IBD
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 05 December 2017 
Childhood obesity into adulthood

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us